André-René Blaudszun

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Endoplasmic Reticulum Stress

Diffuse Large B Cell Lymphoma

Top Venues

Journal of cancer research and clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

André-René Blaudszun, Woo Jun Kim, Wooram Um, Hong Yeol Yoon, Man Kyu Shim, Kwangmeyung Kim
Adoptive Transfer of Photosensitizer-Loaded Cytotoxic T Cells for Combinational Photodynamic Therapy and Cancer Immuno-Therapy. Pharmaceutics 15 (4) (2023)
André-René Blaudszun, Woo Jun Kim, Wooram Um, Hong Yeol Yoon, Man Kyu Shim, Kwangmeyung Kim
Adoptive Transfer of Photosensitizer-Loaded Cytotoxic T Cells for Combinational Photodynamic Therapy and Cancer Immuno-Therapy. Pharmaceutics 15 (4) (2023)
André-René Blaudszun, Woo Jun Kim, Wooram Um, Hong Yeol Yoon, Man Kyu Shim, Kwangmeyung Kim
Adoptive Transfer of Photosensitizer-Loaded Cytotoxic T Cells for Combinational Photodynamic Therapy and Cancer Immuno-Therapy. Pharmaceutics 15 (4) (2023)
André-René Blaudszun, Woo Jun Kim, Wooram Um, Hong Yeol Yoon, Man Kyu Shim, Kwangmeyung Kim
Adoptive Transfer of Photosensitizer-Loaded Cytotoxic T Cells for Combinational Photodynamic Therapy and Cancer Immuno-Therapy. Pharmaceutics 15 (4) (2023)
Sabine Kürzel, André-René Blaudszun, Lilly Stahl, Regina Herbst, Frank Kroschinsky, Josef Birkmann, Annette Hänel, Kerstin Schaefer-Eckart, Gerhard Ehninger, Friedrich Fiedler, Martin Bornhäuser, Stephan Fricke, Mathias Hänel
Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years. Journal of cancer research and clinical oncology (2022)
Sabine Kürzel, André-René Blaudszun, Lilly Stahl, Regina Herbst, Frank Kroschinsky, Josef Birkmann, Annette Hänel, Kerstin Schaefer-Eckart, Gerhard Ehninger, Friedrich Fiedler, Martin Bornhäuser, Stephan Fricke, Mathias Hänel
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years. Journal of cancer research and clinical oncology (2021)